PetIQ, Inc. (NASDAQ:PETQ) Shares Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. boosted its holdings in PetIQ, Inc. (NASDAQ:PETQGet Rating) by 12.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,085 shares of the company’s stock after buying an additional 1,209 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in PetIQ were worth $186,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Fulcrum Asset Management LLP acquired a new position in shares of PetIQ in the 1st quarter worth $1,574,000. Acuitas Investments LLC purchased a new position in PetIQ in the 1st quarter worth about $3,628,000. Amalgamated Bank acquired a new stake in PetIQ during the 1st quarter worth about $107,000. Swiss National Bank lifted its stake in PetIQ by 8.3% during the first quarter. Swiss National Bank now owns 58,600 shares of the company’s stock valued at $1,430,000 after buying an additional 4,500 shares in the last quarter. Finally, Boston Partners boosted its holdings in shares of PetIQ by 1.9% in the first quarter. Boston Partners now owns 1,570,477 shares of the company’s stock worth $38,264,000 after buying an additional 29,205 shares during the period.

Analysts Set New Price Targets

Several brokerages recently commented on PETQ. Jefferies Financial Group reduced their price target on shares of PetIQ to $21.00 in a research report on Wednesday, September 21st. Raymond James reduced their target price on PetIQ from $21.00 to $16.00 and set an “outperform” rating for the company in a report on Tuesday, October 25th.

PetIQ Price Performance

Shares of PETQ opened at $11.17 on Friday. The business’s 50-day moving average is $8.43 and its 200-day moving average is $13.08. The company has a debt-to-equity ratio of 2.07, a current ratio of 2.90 and a quick ratio of 1.63. The company has a market capitalization of $328.51 million, a price-to-earnings ratio of -5.88, a P/E/G ratio of 1.68 and a beta of 1.63. PetIQ, Inc. has a fifty-two week low of $6.66 and a fifty-two week high of $25.40.

PetIQ (NASDAQ:PETQGet Rating) last released its quarterly earnings data on Wednesday, November 9th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.12. The firm had revenue of $209.73 million for the quarter, compared to analyst estimates of $203.90 million. PetIQ had a negative net margin of 5.94% and a positive return on equity of 10.46%. Equities research analysts expect that PetIQ, Inc. will post 0.87 EPS for the current fiscal year.

PetIQ Company Profile

(Get Rating)

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications.

Featured Stories

Want to see what other hedge funds are holding PETQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetIQ, Inc. (NASDAQ:PETQGet Rating).

Institutional Ownership by Quarter for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.